Cetuximab trials for Lung cancer

All Cetuximab trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Cetuximab for Lung cancer

• A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
  NCT07286149 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
  NCT05910827 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
  NCT06764771 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
  NCT07300150 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
  NCT06179160 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
  NCT07223047 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
  NCT06835569 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• AK129 Combination Therapy for Advanced Solid Tumors
  NCT06943820 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer
  NCT06917079 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
  NCT05504278 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
  NCT07216105 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
  NCT07252739 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
  NCT06586515 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 104 locations
• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
  NCT05786924 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
  NCT07468071 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 20 locations
• Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
  NCT07349537 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
  NCT04485013 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 41 locations

Common questions

How many trials study Cetuximab for Lung cancer?

18 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.